September 27, 2022

Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA

The US Food and Drug Administration (FDA) has reviewed and accepted the protocol for the ONCOS-102 phase 2 combination trial in PD-1 checkpoint inhibitor (CPI) refractory advanced...
Read more
September 23, 2022

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC

STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hem...
Read more
September 22, 2022

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic leth...
Read more
September 22, 2022

Vicore announces that C21 promotes vascular function in humans

Clinically relevant doses of C21 increase blood flow in humansSystemic blood pressure was unaffected, and no side effects were observedThe forearm blood flow method is a robust te...
Read more
September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and otherserious disorders Combined compa...
Read more
September 20, 2022

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published

STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hem...
Read more
September 15, 2022

Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease

Philadelphia, PA, September 15, 2022 --- Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced th...
Read more
September 15, 2022

Vicore provides an update on the ATTRACT-3 COVID-19 trial

ATTRACT-3 did not meet its primary endpoint, reduction of all-cause mortality at 60 daysLack of effect explained by new virus mutationsNo safety signals detected  The company...
Read more
September 12, 2022

Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies

Company to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases  Pretzel founded by leading academic experts in mitoch...
Read more
September 12, 2022

Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds

Brussels, Belgium and Berlin, Germany, 12 September 2022 – Precirix NV and Eckert & Ziegler Eurotope GmbH (Eckert & Ziegler) have signed a collaboration agreement f...
Read more
Older news →